Agreed, Sandoz/Novartis seems to specialize in pre-approval drug manufacture, based not only on its lightening quick, Enoxaparin launch three summers ago, but also on its near pre-approval Gleevec launch, as dramatically described in The Magic Cancer Bullet (2004,) (recommended by Biomaven-thx).
Market Data 
Markets 
AI
